文献速递淋巴瘤

Glofitamab治疗复发或难治性B细胞淋巴瘤的I期试验

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
PubMed 文献 · J Clin Oncol · 2021-03-19

Glofitamab是一种新型2:1结构CD20×CD3双特异性抗体,在复发或难治性B细胞非霍奇金淋巴瘤患者中开展I期试验,所有患者先接受1000 mg奥妥珠单抗预处理。171例可评估患者中,细胞因子释放综合征发生率为50.3%(3-4级3.5%),总体缓解率53.8%(完全缓解36.8%),推荐II期剂量组完全缓解率达57.1%,且完全缓解持久。

要点

  • 奥妥珠单抗预处理后Glofitamab安全性可控,细胞因子释放综合征多为低级别。
  • 推荐II期剂量下完全缓解率达57.1%,且多数完全缓解持久。
  • 对既往多线治疗失败的难治性侵袭性B细胞淋巴瘤仍显示良好活性。

核心结论

  • 在主要为难治性侵袭性B细胞非霍奇金淋巴瘤患者中,Glofitamab显示出良好活性,完全缓解频繁且持久,安全性可预测且可控。

研究设计与样本

  • I期剂量递增研究,采用贝叶斯连续重评估方法并控制过量,所有患者首剂Glofitamab前7天接受1000 mg奥妥珠单抗预处理。
  • 171例患者接受至少一剂Glofitamab,中位既往治疗线数为3,155例(90.6%)对既往治疗难治。

主要发现

  • 细胞因子释放综合征发生于86/171例(50.3%),3级或4级占3.5%;2例(1.2%)出现3级短暂性免疫效应细胞相关神经毒性综合征样症状。
  • 5例(2.9%)因不良事件退出治疗。
  • 所有剂量组总体缓解率为53.8%,完全缓解率36.8%;推荐II期剂量组总体缓解率65.7%,完全缓解率57.1%。
  • 63例完全缓解患者中,53例(84.1%)完全缓解持续,最长观察27.4个月。

临床怎么用

  • 对既往多线治疗失败的难治性侵袭性B细胞淋巴瘤,Glofitamab联合奥妥珠单抗预处理可考虑作为一种治疗选择。
  • 治疗中需监测细胞因子释放综合征和免疫效应细胞相关神经毒性综合征样症状,多数为低级别且可管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Glofitamab is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. This phase I study evaluated glofitamab in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). Data for single-agent glofitamab, with obinutuzumab pretreatment (Gpt) to reduce toxicity, are presented. METHODS: Seven days before the first dose of glofitamab (0.005-30 mg), all patients received 1,000 mg Gpt. Dose-escalation steps were determined using a Bayesian continuous reassessment method with overdose control. Primary end points were safety, pharmacokinetics, and the maximum tolerated dose of glofitamab. RESULTS: Following initial single-patient cohorts, 171 patients were treated within conventional multipatient cohorts and received at least one dose of glofitamab. This trial included heavily pretreated patients with R/R B-NHL; most were refractory to prior therapy (155; 90.6%) and had received a median of three prior therapies. One hundred and twenty-seven patients (74.3%) had diffuse large B-cell lymphoma, transformed follicular lymphoma, or other aggressive histology, and the remainder had indolent lymphoma subtypes. Five (2.9%) patients withdrew from treatment because of adverse events. Cytokine release syndrome occurred in 86 of 171 (50.3%) patients (grade 3 or 4: 3.5%); two (1.2%) patients experienced grade 3, transient immune effector cell-associated neurotoxicity syndrome-like symptoms. The overall response rate was 53.8% (complete response [CR], 36.8%) among all doses and 65.7% (CR, 57.1%) in those dosed at the recommended phase II dose. Of 63 patients with CR, 53 (84.1%) have ongoing CR with a maximum of 27.4 months observation. CONCLUSION: In patients with predominantly refractory, aggressive B-NHL, glofitamab showed favorable activity with frequent and durable CRs and a predictable and manageable safety profile.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. J Clin Oncol. 2021. PMID: 33739857. doi:10.1200/JCO.20.03175

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。